Massachusetts-based Luminopia landed an FDA De Novo for its virtual reality digital therapeutic focused on helping children improve amblyopia, commonly called lazy eye, Mobi Health News reports.
The therapy, called Luminopia One, is geared toward children living with the condition between the ages of 4 and 7 and is focused on improving their visual acuity. Children put on a VR headset and are then shown “therapeutically modified” TV shows and movies. The patient and caregiver can choose from a variety of media content, and the system then uses algorithms to modify the selected content to help a child’s brain take in stimuli from both of their eyes. Read more.
